FindTrial
Sign In

Effect of Mahakalyanaka oil as nasal drop and oral medication along with regular treatment in Parkinsons Disease.

AN OPEN LABEL RANDOMIZED CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY OF MAHAKALYANAKA TAILA NASYA AND PANA AS AN ADJUVANT TO STANDARD OF CARE IN KAMPAVATA vis vis PARKINSONS DISEASE - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/02/104114
Enrollment
40
Registered
2026-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20- Parkinsons disease

Interventions

None listed

Sponsors

Dr Mandara Shetty V
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects diagnosed with Kampavata (Parkinson s disease) who fulfill mentioned diagnostic criteria. 2.Subjects between the age group of 50-70 years irrespective of gender, religion, occupation and their socio-economic status. 3.Subjects with Standard of Care in Parkinson s Disease. 4.Subjects willing to give informed consent and participate in the study.

Exclusion criteria

Exclusion criteria: 1.Subjects diagnosed with Neuro-Degenerative Diseases such as Alzheimer s disease and others which interfere with the course of treatment. 2.Subjects diagnosed with Movement disorder such as Huntington s disease, Multiple system Atrophy and others which interfere with the course of treatment. 3.Subjects diagnosed with systemic diseases such as Diabetic Autonomic Neuropathy, Cardiac Diseases and others which interfere with the course of treatment. 4.Subjects diagnosed with Endocrinal diseases such as Hypoparathyroidism and Metabolic Disorders such as Dyslipidemia, Obesity and others which interfere with course of treatment. 5.Subjects diagnosed with Psychiatric diseases such as Schizophrenia, Bipolar disorder and others which interfere with the course of treatment. 6.Subjects diagnosed with Brain Tumor. 7.Subjects unfit for Nasya and Shamana Sneha.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of Standard of Care and Mahakalyanaka taila Nasya and Pana as an adjuvant to Standard of Care in Kampavata vis- -vis Parkinson s Disease.Timepoint: After Nasya on 8th day After Shamana Sneha on 38th day—

Secondary

MeasureTime frame
To evaluate the efficacy of Mahakalyanaka Taila Nasya & Pana as an adjuvant to Standard of Care in Kampavata vis a vis Parkinsons Disease. To evaluate the effect of Standard of Care in Kampavata vis a vis Parkinsons Disease. Timepoint: After Nasya on 8th day After Shamana Sneha on 38th day—

Countries

India

Contacts

Public ContactDr Deepa C Patil

JSS Ayurveda Medical College and Hospital

deepsmysore@gmail.com9886485005

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026